Rajiv Jain’s GQG Partners Portfolio: 5 Dividend Stock Picks

In this article, we will discuss 5 dividend stocks in Rajiv Jain’s portfolio. To take a look at more stocks and a detailed analysis of GQG Partners’ past performance and recent developments, go directly to Rajiv Jain’s GQG Partners Portfolio: 10 Dividend Stock Picks. 

5. AstraZeneca PLC (NASDAQ:AZN)

Number of Hedge Fund Holders: 42
GQG Partners’ Stake Value: $1,132,984,000
Dividend Yield as of March 14: 3.96%

In February, British-Swedish pharmaceutical company AstraZeneca PLC (NASDAQ:AZN), was initiated with a ‘Buy’ rating by Stifel, with a 12,300 GBP price target. The firm predicts the company will be one of the fastest-growing big pharma companies, with a substantially positive growth rate over the next five years. AstraZeneca PLC (NASDAQ:AZN) currently pays a quarterly dividend of $1.97 per share. The stock’s dividend yield, as of March 14, stood at 3.96%.

At the end of Q4 2021, GQG Partners held shares worth over $1.1 billion in AstraZeneca PLC (NASDAQ:AZN) after increasing its position by 6% during the quarter. The company made up 2.8% of Rajiv Jain’s portfolio. By the end of Q4 2021, 42 hedge funds tracked by Insider Monkey held stakes in AstraZeneca PLC (NASDAQ:AZN), up from 41 in the previous quarter. Those stakes were valued at nearly $4 billion.